Research & Development
Isla announces Brazilian patent for Isla101 for development of treatment for mosquito borne viruses
20 October 2020 -

Drug repurposing company Isla Pharmaceuticals reported on Monday the receipt of the key patent for its lead Isla101 programme on 29 September 2020 from the Brazilian Industrial Property Office under the Brazil Patent No BR 112015026243-0..

According to the company, Isla101, a drug with a well understood safety profile, is being repurposed for the potential prevention and treatment of mosquito borne (or vector) diseases including dengue, Zika and others that represent major unmet medical needs in Brazil.

Brazil generally has the greatest number of dengue cases in the world, with more than two million cases 2019 alone. The country has also been severely affected by outbreaks of Zika virus and chikungunya in the last few years.

In conjunction with the patent, Isla has licensed an IP portfolio from the Monash University, with focus on the use of molecules for the prevention and treatment of mosquito borne viruses.

The company is advancing Isla101 towards a Phase II clinical trial in dengue-infected subjects and upon US FDA approval and meeting certain other criteria, it may be eligible to obtain a Priority Review Voucher, which will permit to expedite the FDA approval process for a new drug, or sell the PRV in a secondary market. The PRVs reportedly attracts USD75m-USD150m.

Login
Username:

Password: